ArticlePLoS neglected tropical diseases2020
Evaluation of six commercial kits for the serological diagnosis of Mediterranean visceral leishmaniasis.
Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Global Landscape of Molecular and Immunological Diagnostic Tests for Human Leishmaniasis: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2025Pooled it
- Leishmaniasis in deployed military populations: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Molecular diagnostics for cutaneous leishmaniasis: progress towards fulfilling the WHO target product profile.Parasitology · 2025Review
- Recombinant Leishmania-activated C kinase as a novel antigenic candidate for immuno-diagnosis of visceral leishmaniasis occurring in India and Brazil.Infectious diseases of poverty · 2025Article
- Impact of age and immune status on the accuracy of rapid diagnostic tests for visceral leishmaniasis in Brazil.PLoS neglected tropical diseases · 2025Article
- Visceral Leishmaniasis in Pediatrics: A Case Series and a Narrative Review with Global Insights.Tropical medicine and infectious disease · 2025Review
- Advances and Challenges in the Diagnosis of Leishmaniasis.Molecular diagnosis & therapy · 2025Review
- Seroprevalence of dengue, Zika, and chikungunya in São Sebastião, Brazil (2020-2021): a population-based survey.BMC infectious diseases · 2025Article
- Comparison of ELISA and IFAT for Leishmania infantum by European and Middle Eastern diagnostic laboratories.Parasites & vectors · 2024Article
- Simplified molecular diagnosis of visceral leishmaniasis: Laboratory evaluation of miniature direct-on-blood PCR nucleic acid lateral flow immunoassay.PLoS neglected tropical diseases · 2024Article
- Asymptomatic Leishmania infantum infection in dogs and dog owners in an endemic area in southeast France.Parasite (Paris, France) · 2024Article
- Prevalence of asymptomatic Leishmania infection and knowledge, perceptions, and practices in blood donors in mainland Portugal.Parasites & vectors · 2023Article
- Updated diagnosis and graft involvement for visceral leishmaniasis in kidney transplant recipients: a case report and literature review.Infection · 2023Review
- The immune response in canine and human leishmaniasis and how this influences the diagnosis- a review and assessment of recent research.Frontiers in cellular and infection microbiology · 2023Review
- Serology for visceral leishmaniasis: How trusty is the accuracy reported by the manufacturers?Revista da Sociedade Brasileira de Medicina Tropical · 2023Review
- An Overview on Leishmaniasis in Romania: Diagnosis and Therapeutics.Tropical medicine and infectious disease · 2022Review
- Article
- Tissue/Biofluid Specific Molecular Cartography ofFrontiers in cellular and infection microbiology · 2021Article
- Serodiagnosis of Visceral Leishmaniasis in Northeastern Italy: Evaluation of Seven Serological Tests.Microorganisms · 2020Article
- Recent advances and new strategies in Leishmaniasis diagnosis.Applied microbiology and biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZoonotic visceral leishmaniasis (VL) is endemic in the Mediterranean basin. However, large-scale comparative analyses of the commercial kits for the serological diagnosis of this neglected disease are lacking. This study compared the performances of four enzyme-linked immunosorbent assays (ELISA) and two immunochromatographic tests (ICT) as screening tests for the serodiagnosis of human VL in the Mediterranean region. METHODOLOGY/PRINCIPAL
findingsSerum samples from 319 patients living in France, Tunisia or Morocco were tested using two ICT (IT LEISH and TruQuick LEISH IgG/IgM Meridian) and four ELISA reagents (NovaLisa Leishmania infantum IgG, Bordier Leishmania infantum, Ridascreen Leishmania IgG, and Vircell Leishmania). The population with proven VL (n = 181) included 65 immunocompromised patients. Significantly higher percentages of false-negative results were obtained with all assays in immunocompromised patients, compared with the immunocompetent population. In the whole population, sensitivity and specificity ranged from 80.7% to 93.9% and from 95.7% to 100%, respectively. The maximum accuracy was observed with the Bordier and Vircell ELISA kits (96.2%), and the lowest accuracy with Ridascreen reagent (88.7%). New thresholds of positivity are proposed for the Bordier, Vircell and NovaLisa ELISA kits to achieve 95% sensitivity with the highest possible specificity. Western blot (WB), used as a confirmation method, showed 100% sensitivity and identified 10.1% of asymptomatic carriers among the control population from the South of France. CONCLUSIONS/SIGNIFICANCE: This is the first study that compared commercially available kits for VL serodiagnosis in the endemic region of the Mediterranean basin. It provides specific information about the tests' performance to help clinicians and biologists to select the right assay for VL screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.